The FDA's Decision to Remove Later Line Opportunities for PARP Patients

The NCCN guidelines are you know one of the main guidelines that we look at do not align with the FDA guidelines right now. So in treatment and I disagree I have great respect and admiration for FDA colleagues they are colleagues okay but I don't know if I quite understand the decision that was made based on the data which was presented to remove later line opportunities for PARP patients. 50 percent of patients will have will come into practice with recurrence who have not had a PARP inhibitors. How many of those ultimately depends on how they respond to platinum in the recurrence setting.